Member Info for alamo55

DRO Mich.....you can't invest if you're in one of them....just another 6 years fir you to wait 😏🤘

......along at 5p.......soon we'll be sprinting at 85p...spring is on its way!🔥👍😎💷💷

....shares has this mystery dumper got to sell still? Why do they want to sell? It would be interesting to find out as it's been going for a long time now.

......£2.60? There's some strange titbits on X, I don't believe any pirates on there☠️

Nothing to do with here Troajan, wrong board!

The old 1 share buyer is back, not that I believe what it means, but it's interesting, especially on a Friday.👍🙂

....since Lionsgold was taken off aim, tally? just another name for CP's pension pot, promises promises have led to nothing, I'm nearly 70 not in good health...I'll be dead before it relists!!! I could think of a few other words CP stands for!!!😡😡

Wow!....I'm sure CT has noticed the RNS from GSK this morning....1 billion up front payment to Aiolos...and they're only at phase 2!......more fuel to the fire for his negotiations, its bubbling under nicely and the herd haven't even arrived yet!!💰💰💷💷💥💥

Cheers, Alamo👍😁

Week

Good investment opportunities come around when excellent companies are surrounded by unusual circumstances that cause the stock to be misappraised.

Some good news from my younger sister who works for Barrons funds in NY, one of the in sectors atm which funds are latching onto is the biopharma sector this year as there are a lot of underappreciated companies at a low valuation. Included in the conversation were the UK and Indian sector, India especially as she highlighted that their economy would grow the most this year. US funds have a lot of spare cash to invest so judging by that we can expect a few surprises on the horizon. Let's hope Destiny can get a good deal as the signs look good.

Cheers, alamo 👍🤘

.....15.30

As per info research on my first message, Roche are only in the news because of the fact they are a well known company. Get this...."we are a very long way" from it being used in hospitals Prof Piddock said!!

"Full clinical trials... take a lot of time, several years ( average 10), and indeed they cost millions of pounds to do. Even if the trial is successful, then the drug has to be approved for use and then made accessible to those that need it - and that is all over the world not just in a few countries that can afford it.

"Therein is the big problem - the economics of making antibiotics."

Despite the considerable hurdles, there is "definite hope".

"It is really exciting - and not only is it good for this type of bacteria, but this could be built upon for others as well," Prof Piddock added.

XF73 is much further along the track, when the big boys realise this then I expect all hell to let loose, and us, Destiny Pharma, will be highly regarded as an innovative company. So far under the radar it's unbelievable! Earthquake waiting to happen.!!💥💥

Cheers, Alamo👍😁💉💉

After seeing the new antibiotic Zosurabalpin in the news today from Roche I discovered this : Acinetobacter Infections Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline Acinetobacter infections therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acinetobacter infections pipeline domain.

Key Takeaways from the Acinetobacter Infections Pipeline Report

DelveInsight’s Acinetobacter infections pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Acinetobacter infections treatment.

Key Acinetobacter infections companies such as Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, DESTINY PHARMA,BioVersys, HOFFMAN LA-ROCHE, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others are evaluating novel Acinetobacter infections drug candidates to improve the treatment landscape.

Zosurabalpin is Roche's baby and it's in the major news on tv because of the size of Roche but it operates in the same sphere as Destiny!! Once XF 73 gets the same promenance then it'll be a blockbuster, we're talking not millions but billions, I've upped it to a strong buy!

Cheers alamo 🔥🔥🚀🚀🥳

....almost reached 29.80!!🔥

I'm sure CT is well aware of the cash situation and will know the deal will need to be sorted well before '25. What this update says to me is that he won't be sold short by certain large Pharma's coming in with an offer which is derisory, he will have a figure in mind and won't go below that based on what XF 73 is worth.🥂🚀

Finally, at least as regards money, I see that the Mail on Sunday have alighted upon IDS for 2024. I reckon they are right. Their new sorting office, near Daventry, is the size of 30 football pitches. That rather puts Amazon in their place. Buy at 280p.

....what can be achieved if you get a big partner re the c4xd deal today with Astra Zeneca, buys coming in because when our deal is struck it'll be ten times bigger!

🚀🚀🚀🎉🎉🥳

Critical Metals: 9.75p Target 25p Stop Loss 6p

At the start of 2023 shares of Critical Metals (CRTM) were very much on a high, boosted not only by the market’s enthusiasm for its flagship Molulu copper-cobalt project in the Democratic Republic of Congo, but also the dynamism of CEO Russell Fryer. Fast forward to October and the company said it entered into an offtake agreement with OM Metal & Resources SARL, for the sale of at least 20,000 tonnes of copper oxide ore. This month’s operational update underlined that the first ore sales are due by the end of Q1 2024. If you add in the sizzle from the latest 24-drill-hole campaign at Molulu, and the current share price vs 30p plus at the start of the year, CRTM not only seems the wrong price, but this is classic situation which underlines how short term traders have exited, just before the fundamental party is set to begin.

Rabbit Out Of A Hat

A category that played a big role in at least some of the winners of 2023 was the ability of a company to pull a rabbit out of a hat, wrongfooting a cynical / negative market by proving its worth. One could argue that Destiny Pharma (DEST) did this twice in the last year, the first time in July with the return of the former Chairman, and then on positive data regarding its flagship XF-73. Given ongoing stock market conditions, small caps will need to engage in rabbit pulling of Magic Circle proportions during the course of 2024.

It's a hang loose situation, news about the deal can come anytime this month🥂🥳

CleanTech Lithium: 19.75p Target 40p Stop Loss 14.5p

Given the way that nearly a fifth of all new cars are now electric, one would have thought that any stock even vaguely related to lithium would have been roaring. Clearly, this has not been the case, although it should be said that for the beginning of 2023, shares of CleanTech (CTL) were very much on the front foot, as the market celebrated the way that the company was mobilising its assets. Highlights at the time included a scoping study confirming the potential of the Laguna Verde project, as well as the announcement of a proposed listing on the ASX. However, concerns over jurisdiction risk in Chile pulled the rug from under the shares, even though CTL was effectively set up to be a plug and play in that country. Subsequently, none of the market’s fears regarding Chile’s plans for its lithium industry proved to be founded. As we go into 2024, with the over £8m raise to advance its projects, we should see the shares rebound off their recent lows, if only on the basis of the merit of Laguna Verde and Francisco Basin.

(22nd*)